Ildefonso RodrÃ-guez-Leyva

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3983490/publications.pdf

Version: 2024-02-01

75 papers

4,652 citations

361388 20 h-index 197805 49 g-index

83 all docs 83 docs citations

83 times ranked 7277 citing authors

#	Article	IF	CITATIONS
1	Clinical guideline: pre-operative evaluation of epilepsy surgery. Revista Mexicana De Neurociencia, 2022, 20, .	0.2	O
2	Characterization and classification of Parkinson's disease patients based on symbolic dynamics analysis of heart rate variability. Biomedical Signal Processing and Control, 2022, 71, 103064.	5.7	4
3	Cryptococcal meningitis due to <i>Cryptococcus gattii</i> in an immunocompetent patient: uncommon presentation of a thunderclap headache. BMJ Case Reports, 2022, 15, e246158.	0.5	2
4	Unusual complication of Herpes simplex encephalitis: complete Klüver-Bucy syndrome. BMJ Case Reports, 2022, 15, e250745.	0.5	0
5	Clinical guideline: status epilepticus in children and adults. Revista Mexicana De Neurociencia, 2021, 20, .	0.2	0
6	Challenging presentation of primary vasculitis of the central nervous system. Cerebral Circulation - Cognition and Behavior, 2021, 2, 100027.	0.9	1
7	Comprehensive management of adults with chronic migraine: Clinical practice guidelines in Mexico. Cephalalgia Reports, 2021, 4, 251581632110339.	0.7	O
8	Virus, Immunity and Human Neurodegenerative Diseases. A Perspective. Acta Scientific Microbiology, 2021, 4, 34-36.	0.1	0
9	January 2020 Mexican Journal of Neuroscience. Revista Mexicana De Neurociencia, 2021, 21, .	0.2	O
10	Joker in real life. Revista Mexicana De Neurociencia, 2021, 21, .	0.2	0
10	Joker in real life. Revista Mexicana De Neurociencia, 2021, 21, . Irreversible modifications of chromatin and the nuclear lamina: A review inside the nuclear origin of Alzheimer's disease. Revista Mexicana De Neurociencia, 2021, 22, .	0.2	0
	Irreversible modifications of chromatin and the nuclear lamina: A review inside the nuclear origin of		
11	Irreversible modifications of chromatin and the nuclear lamina: A review inside the nuclear origin of Alzheimer's disease. Revista Mexicana De Neurociencia, 2021, 22, . ¿SÃndrome del Guasón, caracterÃstica distintiva de neuro-Behçet?. ReumatologÃa ClÃnica, 2021, 17,	0.2	0
11 12	Irreversible modifications of chromatin and the nuclear lamina: A review inside the nuclear origin of Alzheimer's disease. Revista Mexicana De Neurociencia, 2021, 22, . ¿SÃndrome del Guasón, caracterÃstica distintiva de neuro-Behçet?. ReumatologÃa ClÃnica, 2021, 17, 368-369. Catatonic syndrome as the presentation of encephalitis in association with COVID-19. BMJ Case	0.2	0
11 12 13	Irreversible modifications of chromatin and the nuclear lamina: A review inside the nuclear origin of Alzheimer's disease. Revista Mexicana De Neurociencia, 2021, 22, . ¿SÃndrome del Guasón, caracterÃstica distintiva de neuro-Behçet?. ReumatologÃa ClÃnica, 2021, 17, 368-369. Catatonic syndrome as the presentation of encephalitis in association with COVID-19. BMJ Case Reports, 2021, 14, e240550. Neurological disease and behavioral changes in the human being. Revista Mexicana De Neurociencia,	0.2 0.5	0 0 10
11 12 13	Irreversible modifications of chromatin and the nuclear lamina: A review inside the nuclear origin of Alzheimer's disease. Revista Mexicana De Neurociencia, 2021, 22, . ¿SÃndrome del Guasón, caracterÃstica distintiva de neuro-Behçet?. ReumatologÃa ClÃnica, 2021, 17, 368-369. Catatonic syndrome as the presentation of encephalitis in association with COVID-19. BMJ Case Reports, 2021, 14, e240550. Neurological disease and behavioral changes in the human being. Revista Mexicana De Neurociencia, 2021, 22, .	0.2 0.5	0 0 10
11 12 13 14	Irreversible modifications of chromatin and the nuclear lamina: A review inside the nuclear origin of Alzheimer's disease. Revista Mexicana De Neurociencia, 2021, 22, . ¿SÃndrome del Guasón, caracterÃstica distintiva de neuro-BehÃ\$et?. ReumatologÃa ClÃnica, 2021, 17, 368-369. Catatonic syndrome as the presentation of encephalitis in association with COVID-19. BMJ Case Reports, 2021, 14, e240550. Neurological disease and behavioral changes in the human being. Revista Mexicana De Neurociencia, 2021, 22, . ALS Policy in Mexico. , 2021, , 191-199. Practical needs and considerations for refugees and other forcibly displaced persons with neurological disorders: Recommendations using a modified Delphi approach. Gates Open Research,	0.2 0.5 0.5	0 0 10 0

#	Article	IF	Citations
19	Perinuclear Lamin A and Nucleoplasmic Lamin B2 Characterize Two Types of Hippocampal Neurons through Alzheimer's Disease Progression. International Journal of Molecular Sciences, 2020, 21, 1841.	4.1	22
20	Dosing Recommendations Based on Population Pharmacokinetics of Lamotrigine in Mexican Adult Patients With Epilepsy. Journal of Pharmaceutical Sciences, 2020, 109, 2902-2908.	3.3	3
21	Population Pharmacokinetics and Dosing Recommendations of Levetiracetam in Adult and Elderly Patients With Epilepsy. Journal of Pharmaceutical Sciences, 2020, 109, 2070-2078.	3.3	14
22	Tuberculosis in the Central Nervous System. Acta Scientific Microbiology, 2020, 3, 01-07.	0.1	0
23	Nervous system and COVID-19. Revista Mexicana De Neurociencia, 2020, 21, .	0.2	0
24	Individual health reflected in the collectivity. Revista Mexicana De Neurociencia, 2020, 21, .	0.2	0
25	A light at the end of the tunnel. Revista Mexicana De Neurociencia, 2020, 21, .	0.2	0
26	Early Diagnosis of Neuropathy in Individuals with Family History for Diabetes Mellitus Type 2. Techniques in Neurosurgery & Neurology, 2020, 3, .	0.0	0
27	Nuevo sensor desechable para medir la presión intraabdominal. CirugÃa Y Cirujanos, 2020, 88, 7-14.	0.1	2
28	A relationship between drug-resistant epilepsy and structural abnormalities in neuroimaging. Revista Mexicana De Neurociencia, 2020, 21, .	0.2	0
29	Meningeal Tuberculosis Presented As A Myasthenia Gravis Picture. Acta Scientific Microbiology, 2020, 3, 15-20.	0.1	2
30	Hemichoreaâ€Hemiballism: An Uncommon Presentation of Central Nervous System Tuberculosis. Movement Disorders Clinical Practice, 2020, 7, S77-S79.	1.5	2
31	Determination of Levetiracetam in Plasma by a Modified HPLC-UV Method and Its Pharmacokinetic Application. Mathews Journal of Pharmaceutical Science, 2020, 4, .	0.0	0
32	A brief background of Neurology in Mexico. Revista Mexicana De Neurociencia, 2020, 21, .	0.2	0
33	Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet, The, 2019, 394, 1352-1363.	13.7	433
34	Late onset adrenoleukodystrophy: A review related clinical case report. ENeurologicalSci, 2019, 14, 62-67.	1.3	6
35	Multiple system atrophy. International Review of Neurobiology, 2019, 149, 137-192.	2.0	74
36	Low levels of alpha-synuclein in peripheral tissues are related to clinical relapse in relapsing-remitting multiple sclerosis: a pilot cross-sectional study. Journal of the Neurological Sciences, 2019, 396, 87-93.	0.6	4

#	Article	IF	Citations
37	Disseminated Nocardiosis: A Case Report. Cureus, 2019, 11, e5294.	0.5	4
38	My point of view. Revista Mexicana De Neurociencia, 2019, 20, .	0.2	O
39	Clinical Presentations and Factors Associated with in-Hospital Mortality of Patients Diagnosed with Subacute and Chronic Infectious Meningitis in A Mexican Hospital. Acta Scientific Microbiology, 2019, 2, 17-24.	0.1	0
40	Vinpocetina de liberación prolongada: un posible tratamiento adyuvante en crisis epiléptica de inicio focal. BoletÃn Médico Del Hospital Infantil De México, 2019, 76, 215-224.	0.3	3
41	Demencia frontotemporal: revisi \tilde{A}^3 n y nuestro punto de vista. Revista Mexicana De Neurociencia, 2019, 19, .	0.2	1
42	Science and Art. Revista Mexicana De Neurociencia, 2019, 20, .	0.2	0
43	Association of white matter diffusion characteristics and cognitive deficits in temporal lobe epilepsy. Epilepsy and Behavior, 2018, 79, 138-145.	1.7	46
44	Potential Pitfalls in the Diagnostic Criteria for Neurocysticercosis: Are Mimmicks Common?. Journal of Neuroinfectious Diseases, 2018, 09, .	0.2	0
45	Usefulness of Ilae 2010 classification in Mexican epilepsy patients. Journal of the Neurological Sciences, 2017, 376, 13-15.	0.6	1
46	The Presence of Alphaâ€Synuclein in Skin from Melanoma and Patients with Parkinson's Disease. Movement Disorders Clinical Practice, 2017, 4, 724-732.	1.5	25
47	The resurgence of meningeal tuberculosis in Mexico: A social phenomenon. Journal of the Neurological Sciences, 2017, 372, 329-330.	0.6	2
48	EpiNet as a way of involving more physicians and patients in epilepsy research: Validation study and accreditation process. Epilepsia Open, 2017, 2, 20-31.	2.4	4
49	Tau Protein in Oral Mucosa and Cognitive State: A Cross-sectional Study. Frontiers in Neurology, 2017, 8, 554.	2.4	8
50	Oxidative Stress Modifies the Levels and Phosphorylation State of Tau Protein in Human Fibroblasts. Frontiers in Neuroscience, 2017, 11, 495.	2.8	24
51	665 Expression of α-Synuclein in melanocytic cells. Journal of Investigative Dermatology, 2016, 136, S117.	0.7	0
52	Comparison of phosphorylated Tau and Ki-67 staining in SCIS, SCC, and BCC. Journal of the American Academy of Dermatology, 2016, 74, AB32.	1.2	0
53	Parkinson disease and progressive supranuclear palsy: protein expression in skin. Annals of Clinical and Translational Neurology, 2016, 3, 191-199.	3.7	29
54	Fluorescence background removal method for biological Raman spectroscopy based on empirical mode decomposition., 2016, 2016, 3610-3613.		4

#	Article	IF	Citations
55	The epinet-first trials now recruiting patients with newly diagnosed epilepsy. Journal of the Neurological Sciences, 2015, 357, e144.	0.6	1
56	International engagement by <scp>U</scp> nited <scp>S</scp> tates academic neurology departments: A national survey. Annals of Neurology, 2015, 78, 150-152.	5.3	3
57	Skin biomarkers for neurodegenerative disease: a future perspective. Neurodegenerative Disease Management, 2015, 5, 465-467.	2.2	2
58	Efficacy and safety of extendedâ€release oxcarbazepine (Oxtellar XRâ,,¢) as adjunctive therapy in patients with refractory partialâ€onset seizures: a randomized controlled trial. Acta Neurologica Scandinavica, 2014, 129, 143-153.	2.1	42
59	αâ€Synuclein inclusions in the skin of Parkinson's disease and parkinsonism. Annals of Clinical and Translational Neurology, 2014, 1, 471-478.	3.7	40
60	Cerebral Venous Thrombosis in a Mexican Multicenter Registry of Acute Cerebrovascular Disease: The RENAMEVASC Study. Journal of Stroke and Cerebrovascular Diseases, 2012, 21, 395-400.	1.6	71
61	Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis. New England Journal of Medicine, 2012, 367, 1098-1107.	27.0	1,493
62	Assessment of Atherothrombosis and Its Treatment in Mexico: Firstâ€Year Data of the REACH Registry. Clinical Cardiology, 2010, 33, 445-451.	1.8	5
63	Paraoxonase gene mutations in amyotrophic lateral sclerosis. Annals of Neurology, 2010, 68, 102-107.	5.3	67
64	Use of Statins for the Treatment of Spontaneous Intracerebral Hemorrhage: Results of a Pilot Study. Central European Neurosurgery, 2009, 70, 15-20.	0.7	54
65	Reduced expression of the <i>Kinesin-Associated Protein 3</i> (<i>KIFAP3</i>) gene increases survival in sporadic amyotrophic lateral sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 9004-9009.	7.1	177
66	Aneurysmal Subarachnoid Hemorrhage in a Mexican Multicenter Registry of Cerebrovascular Disease: The RENAMEVASC Study. Journal of Stroke and Cerebrovascular Diseases, 2009, 18, 48-55.	1.6	26
67	Population pharmacokinetics of valproate in Mexican children with epilepsy. Biopharmaceutics and Drug Disposition, 2008, 29, 511-520.	1.9	29
68	A common haplotype within the PON1 promoter region is associated with sporadic ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2008, 9, 306-314.	2.1	37
69	New <i>VAPB</i> deletion variant and exclusion of <i>VAPB</i> mutations in familial ALS. Neurology, 2008, 70, 1179-1185.	1.1	50
70	Prospective assessment of levetiracetam pharmacokinetics during dose escalation in 4- to 12-year-old children with partial-onset seizures on concomitant carbamazepine or valproate. Epilepsy Research, 2007, 74, 60-69.	1.6	44
71	International Prevalence, Recognition, and Treatment of Cardiovascular Risk Factors in Outpatients With Atherothrombosis. JAMA - Journal of the American Medical Association, 2006, 295, 180.	7.4	1,353
72	Effect of vigabatrin on the pharmacokinetics of carbamazepine. Journal of Clinical Pharmacy and Therapeutics, 2002, 27, 427-430.	1.5	19

#	Article	IF	CITATIONS
73	Exposure to Arsenic and Lead and Neuropsychological Development in Mexican Children. Environmental Research, 2001, 85, 69-76.	7.5	387
74	Plasma concentrations of vigabatrin in epileptic patients. Journal of Clinical Pharmacy and Therapeutics, 1996, 21, 393-398.	1.5	17
75	Practical needs and considerations for refugees and other forcibly displaced persons with neurological disorders: Recommendations using a modified Delphi approach. Gates Open Research, 0, 5, 178.	1.1	0